NASDAQ:INCYIncyte Stock Price, Forecast & News

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INCY stock has increased by 31.2% and is now trading at $94.32.
View which stocks have been most impacted by Coronavirus.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Incyte.

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Incyte.

Incyte Co. (NASDAQ:INCY) released its earnings results on Tuesday, August, 4th. The biopharmaceutical company reported $1.04 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.68 by $0.36. The biopharmaceutical company had revenue of $688 million for the quarter, compared to analysts' expectations of $617.55 million. Incyte had a negative net margin of 8.00% and a negative return on equity of 8.06%. The company's revenue for the quarter was up 29.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.75 EPS.
View Incyte's earnings history.

23 brokers have issued 12 month target prices for Incyte's stock. Their forecasts range from $83.00 to $124.00. On average, they anticipate Incyte's share price to reach $102.30 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price.
View analysts' price targets for Incyte.

Media headlines about INCY stock have trended positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Incyte earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.
View the latest news about Incyte.

Incyte saw a increase in short interest in January. As of January 15th, there was short interest totaling 4,530,000 shares, an increase of 14.7% from the December 31st total of 3,950,000 shares. Based on an average trading volume of 1,410,000 shares, the days-to-cover ratio is currently 3.2 days. Approximately 2.1% of the company's stock are short sold.
View Incyte's Short Interest.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Kite Pharma (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include First Trust Advisors LP (0.89%), Sumitomo Mitsui Trust Holdings Inc. (0.42%), Frontier Capital Management Co. LLC (0.34%), MERIAN GLOBAL INVESTORS UK Ltd (0.34%), Swiss National Bank (0.34%) and Manning & Napier Group LLC (0.22%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Country Trust Bank, Sector Gamma AS, Sumitomo Mitsui Trust Holdings Inc., Russell Investments Group Ltd., QCI Asset Management Inc. NY, BNP PARIBAS ASSET MANAGEMENT Holding S.A., and SG Americas Securities LLC. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon, and Yao Wenqing.
View insider buying and selling activity for Incyte.

INCY stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., Todd Asset Management LLC, Adams Diversified Equity Fund Inc., MERIAN GLOBAL INVESTORS UK Ltd, State of Alaska Department of Revenue, and M&G Investment Management Ltd.. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Jean Jacques Bienaime.
View insider buying and selling activity for Incyte.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INCY stock can currently be purchased for approximately $94.32.

Incyte has a market capitalization of $20.63 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

The official website for Incyte is www.incyte.com.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]